- Conditions
- Anal Cancer
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced May 21, 2026, 6:34 PM EDT